NCT04093882View on ClinicalTrials.gov

The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease

CompletedOBSERVATIONAL
Enrollment

101

Participants

Timeline

Start Date

September 12, 2019

Primary Completion Date

September 30, 2021

Study Completion Date

September 30, 2021

Conditions
Blood Brain BarrierAlzheimer DiseaseCognitive DysfunctionDementia
Interventions
DIAGNOSTIC_TEST

Contrast agent enhanced MRI using Gadovist

By using the contrast agent Gadovist we aim to visualize the blood-brain barrier. Furthermore, we aim to measure a newly developed biomarker of the blood-brain barrier in the cerebro-spinal fluid.

Trial Locations (1)

10117

Charité Universitätsmedizin Berlin, Berlin

All Listed Sponsors
collaborator

Prof. Dr. med. Jochen Fiebach (Senior Physician)

UNKNOWN

lead

Charite University, Berlin, Germany

OTHER

NCT04093882 - The Relevance of the Blood-brain Barrier to Cognitive Dysfunction and Alzheimer's Disease | Biotech Hunter | Biotech Hunter